Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales

Moderna and its rivals Pfizer and Novavax have all seen a steep drop in sales of Covid vaccines and treatments as the world moves on from the pandemic.  

Previous post Warner Bros. Discovery loses subscribers after Max launch, but shares rise on debt paydown
Next post Planet Fitness stock slides premarket after better-than-expected earnings offset by lowered guidance